These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18949607)

  • 1. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Carney DA
    Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
    [No Abstract]   [Full Text] [Related]  

  • 2. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
    Rojewski MT; Körper S; Schrezenmeier H
    Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
    Tajima M
    Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
    [No Abstract]   [Full Text] [Related]  

  • 4. Co-biomodulation with arsenic trioxide in multiple myeloma.
    Gallagher RE
    Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Tamm I; Paternostro G; Zapata JM
    N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 7. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
    Sumi D; Shinkai Y; Kumagai Y
    Toxicol Appl Pharmacol; 2010 May; 244(3):385-92. PubMed ID: 20193703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T; Kees M; Gisslinger H
    Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curing APL: differentiation or destruction?
    Kogan SC
    Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS
    Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
    Wang HX; Duan LN; Ji SQ; Guo ZK
    Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
    [No Abstract]   [Full Text] [Related]  

  • 18. Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
    Fung TK; So CW
    Oncotarget; 2013 Aug; 4(8):1128-9. PubMed ID: 23934744
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide and neuroblastoma cytotoxicity.
    Pettersson HM; Karlsson J; Pietras A; Øra I; Påhlman S
    J Bioenerg Biomembr; 2007 Feb; 39(1):35-41. PubMed ID: 17549641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.